Cargando…

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

Background: Aberrant activation of RAS-RAF-MEK-ERK signaling pathway has been implicated in more than one-third of all malignancies. MEK inhibitors are promising therapeutic approaches to target this signaling pathway. Though four MEK inhibitors have been approved by FDA, these compounds possess eit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yahong, Cheng, Ying, Huang, Gongchao, Xia, Xiangying, Wang, Xingkai, Tian, Hongqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557067/ https://www.ncbi.nlm.nih.gov/pubmed/37808191 http://dx.doi.org/10.3389/fphar.2023.1271268

Ejemplares similares

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
por: Zhao, Qian, et al.
Publicado: (2022)

Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro
por: Huang, Gongchao, et al.
Publicado: (2023)

Current Development Status of MEK Inhibitors
por: Cheng, Ying, et al.
Publicado: (2017)

Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor
por: Hunziker, Daniel, et al.
Publicado: (2022)

Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
por: Kulikov, Andrey, et al.
Publicado: (2021)

Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats
por: Füll, Yvonne, et al.
Publicado: (2022)

Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks
por: Luo, Teng, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
por: Koch-Heier, Julia, et al.
Publicado: (2022)

Structure-Activity Relationships of Pentacyclic Triterpenoids as Potent and Selective Inhibitors against Human Carboxylesterase 1
por: Zou, Li-Wei, et al.
Publicado: (2017)

Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents
por: Yang, Chao, et al.
Publicado: (2022)

Preclinical Evaluation of Safety, Pharmacokinetics, Efficacy, and Mechanism of Radioprotective Agent HL-003
por: Liu, Yahong, et al.
Publicado: (2021)

A mass balance study of [(14)C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
por: Zhang, Hua, et al.
Publicado: (2023)

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
por: Bendell, Johanna C, et al.
Publicado: (2017)

Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension
por: Liparulo, Angela, et al.
Publicado: (2020)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
por: Zhang, Yuejuan, et al.
Publicado: (2022)

Protein phosphatase 6 regulates trametinib sensitivity, a mitogen-activated protein kinase kinase (MEK) inhibitor, by regulating MEK1/2-ERK1/2 signaling in canine melanoma cells
por: YAMAMOTO, Miu, et al.
Publicado: (2023)

Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2
por: Song, Yun-Qing, et al.
Publicado: (2021)

Inhibitors of Human 5-Lipoxygenase Potently Interfere With Prostaglandin Transport
por: Kahnt, Astrid S., et al.
Publicado: (2022)

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
por: Xie, Chengying, et al.
Publicado: (2018)

Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma
por: Wang, Yali, et al.
Publicado: (2023)

Novel Pan-Pim Kinase Inhibitors With Imidazopyridazine and Thiazolidinedione Structure Exert Potent Antitumor Activities
por: Sawaguchi, Yuichi, et al.
Publicado: (2021)

Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent
por: Tian, Xin, et al.
Publicado: (2016)

Discovery of New Potent anti-MERS CoV Fusion Inhibitors
por: Kandeel, Mahmoud, et al.
Publicado: (2021)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

Synthetic approaches to potent heterocyclic inhibitors of tuberculosis: A decade review
por: Dasmahapatra, Upala, et al.
Publicado: (2022)

Monobenzone, a Novel and Potent KDM1A Inhibitor, Suppresses Migration of Gastric Cancer Cells
por: Ma, Peizhi, et al.
Publicado: (2021)

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer
por: Wu, Meng, et al.
Publicado: (2022)

2,6-Bis(2-Benzimidazolyl)Pyridine (BBP) Is a Potent and Selective Inhibitor of Small Conductance Calcium-Activated Potassium (SK) Channels
por: Simó-Vicens, Rafel, et al.
Publicado: (2018)

A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions
por: Lin, Tony Eight, et al.
Publicado: (2018)

Preclinical In vivo Imaging for Fat Tissue Identification, Quantification, and Functional Characterization
por: Marzola, Pasquina, et al.
Publicado: (2016)

Natural Potent NAAA Inhibitor Atractylodin Counteracts LPS-Induced Microglial Activation
por: Yang, Longhe, et al.
Publicado: (2020)

Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
por: Xie, Chun, et al.
Publicado: (2017)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Synthesis, Screening and Characterization of Novel Potent Arp2/3 Inhibitory Compounds Analogous to CK-666
por: Fokin, Artem I., et al.
Publicado: (2022)

OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
por: Hariguchi, Norimitsu, et al.
Publicado: (2020)

Potent block of potassium channels by MEK inhibitor U0126 in primary cultures and brain slices
por: Wang, Jin-Zhao, et al.
Publicado: (2018)

Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies
por: Singla, Rajeev K., et al.
Publicado: (2022)

Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia
por: Pan, Ting, et al.
Publicado: (2022)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Discovery of a Novel Na(v)1.7 Inhibitor From Cyriopagopus albostriatus Venom With Potent Analgesic Efficacy
por: Zhang, Yunxiao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5gthvkl1ui5cbkdi5sjvr2tj36